Related Experiment Videos
Taxol: initial Israeli experience with a novel anticancer agent
1Department of Oncology, Beilinson Medical Center, Petah Tikva, Israel.
Israel Journal of Medical Sciences
|January 1, 1994
Summary
Taxol (paclitaxel) shows efficacy in treating advanced breast and ovarian cancers, even those resistant to other drugs. This study confirms its feasibility and tolerability in Israeli patients, with short infusions being as effective as longer ones.
Area of Science:
- Oncology
- Pharmacology
Background:
- Taxol (paclitaxel), a novel taxane derivative from Taxus brevifolia, exhibits significant antitumor activity.
- Supply and hypersensitivity issues necessitated research for widespread Taxol use.
Purpose of the Study:
- To report the initial experience with Taxol in Israeli patients with advanced breast and ovarian cancers.
- To compare two dose levels and two administration durations (3-hour vs. 24-hour infusion) of Taxol.
Main Methods:
- A total of 107 Israeli patients (38 ovarian, 69 breast cancer) received 706 courses of Taxol.
- Dose levels ranged from 135 to 175 mg/m2.
- Administration durations included 3-hour and 24-hour infusions.
Main Results:
- Taxol administration at 135-175 mg/m2 was feasible.
- 3-hour infusions were as well-tolerated as 24-hour infusions.
- Leukopenia was the main reversible hematological toxicity, more pronounced at higher doses and longer infusions. Alopecia, nausea, vomiting, paresthesias, fatigue, and myalgia were common non-hematological side effects. Allergic reactions and cardiac events were infrequent and mild.
Conclusions:
- Taxol is a feasible and tolerable treatment option for advanced breast and ovarian cancers in Israel.
- Short-duration infusions are effective and well-tolerated.
- Taxol represents a valuable addition to the anticancer chemotherapy armamentarium.